622 related articles for article (PubMed ID: 19681866)
21. Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes.
Tate M; Chong A; Robinson E; Green BD; Grieve DJ
Br J Pharmacol; 2015 Feb; 172(3):721-36. PubMed ID: 25231355
[TBL] [Abstract][Full Text] [Related]
22. Glucagon-like peptide-1 and its cardiovascular effects.
Heo KS; Fujiwara K; Abe J
Curr Atheroscler Rep; 2012 Oct; 14(5):422-8. PubMed ID: 22878937
[TBL] [Abstract][Full Text] [Related]
23. Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection.
Zhao TC
Cardiovasc Diabetol; 2013 Jun; 12():90. PubMed ID: 23777457
[TBL] [Abstract][Full Text] [Related]
24. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects.
Mundil D; Cameron-Vendrig A; Husain M
Diab Vasc Dis Res; 2012 Apr; 9(2):95-108. PubMed ID: 22496442
[TBL] [Abstract][Full Text] [Related]
25. Impact of glucagon-like peptide-1 on endothelial function.
Sjöholm A
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():19-25. PubMed ID: 19878258
[TBL] [Abstract][Full Text] [Related]
26. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
27. Beyond glycemic control: cardiovascular effects of incretin-based therapies.
Angeli FS; Shannon RP
Front Horm Res; 2014; 43():144-57. PubMed ID: 24943305
[TBL] [Abstract][Full Text] [Related]
28. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
Escalada FJ
Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
[TBL] [Abstract][Full Text] [Related]
29. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.
Avogaro A; Vigili de Kreutzenberg S; Fadini GP
Curr Diab Rep; 2014; 14(5):483. PubMed ID: 24676508
[TBL] [Abstract][Full Text] [Related]
31. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S
J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
[TBL] [Abstract][Full Text] [Related]
32. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
[TBL] [Abstract][Full Text] [Related]
33. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Deacon CF
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
[TBL] [Abstract][Full Text] [Related]
34. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
Martin CL
Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067
[TBL] [Abstract][Full Text] [Related]
35. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT; Kieffer TJ
Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
[TBL] [Abstract][Full Text] [Related]
36. The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions.
Girard J
Diabetes Metab; 2008 Dec; 34(6 Pt 1):550-9. PubMed ID: 19036624
[TBL] [Abstract][Full Text] [Related]
37. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
38. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J
Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715
[TBL] [Abstract][Full Text] [Related]
39. Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.
Cariou B
Diabetes Metab; 2012 Oct; 38(4):298-308. PubMed ID: 22672960
[TBL] [Abstract][Full Text] [Related]
40. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
Dupre J
Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
